TRAIL-basednanotherapies offer the potential to improve the stability of TRAIL and prolong itshalf-life in the bloodstream, to specifically deliver TRAIL to target sites and toovercome resistance to TRAIL [33].Compared with direct administration of TRAIL proteins, TRAIL gene therapy also hasthe unique advantages of delivering TRAIL-encoding DNA into tumor cells to locallysecrete the TRAIL protein on the membrane or into the tumor microenvironment,thereby overcoming the limitations of recombinant TRAIL protein. This evidence concerns the gene TNFSF10 and neoplasm.